By admin 
Prasad’s tenure has been nothing short of transformative, albeit deeply divisive. As the head of the Center for Biological Evaluation and Research (CBER) and the FDA’s chief scientific and medical officer, Prasad held the reins of power over the regulation of vaccines, gene therapies, and blood products—sectors that represent the cutting edge of modern medicine. In a social media post, Commissioner Makary lauded Prasad for a list of accomplishments that would typically take years to achieve. These included the reduction of clinical trial requirements for certain drug approvals, the restriction of Covid-19 vaccine recommendations to only those over 65 or with significant risk factors, and the development of a new regulatory pathway for individualized "N-of-1" medicines. Makary also credited Prasad with the successful launch of a "speedy drug review program" intended to bypass traditional bureaucratic hurdles.
However, beneath this veneer of productivity lies an agency in the throes of an identity crisis. Prasad, an oncologist by training who rose to prominence as a "healthcare provocateur" at UCSF, has long been a vocal critic of the pharmaceutical industry and the traditional regulatory process. His academic work often focused on "medical reversal"—the phenomenon where widely adopted medical practices are later found to be ineffective or harmful. When he was brought into the Trump administration’s FDA, he was viewed as a reformer who would challenge the status quo. Yet, his methods have sparked unprecedented pushback from both career scientists within the FDA and external patient advocacy groups.
The timing of Prasad’s departure is particularly notable, following a series of controversial decisions regarding rare disease drugs. Under his leadership, CBER has significantly increased its scrutiny of cell and gene therapies, leading to the rejection of at least five treatments that many experts believe would have been approved under previous administrations. This heightened skepticism has created a paradox within the agency; while Commissioner Makary and other top officials have publicly championed "regulatory flexibility" to help patients with terminal illnesses, Prasad’s center has often acted as a bottleneck. This friction reached a boiling point recently when the Department of Health and Human Services (HHS) took the unconventional step of holding a press call to publicly criticize an experimental Huntington’s disease treatment that was still under regulatory review. Such a move, which bypasses the standard confidential deliberation process, sent shockwaves through the biotech industry and "spooked" rare disease advocates who fear the agency is becoming unpredictable.
Prasad’s relationship with the FDA has been a volatile "on-again, off-again" affair. He originally took over as CBER director in May 2025 but was fired just two months later in July. That initial ouster was the result of a political firestorm involving his handling of a treatment for Duchenne muscular dystrophy, which drew the ire of both rare disease advocates and influential political figures like Laura Loomer, a close ally of President Trump. In a surprising turn of events, the administration reversed course only weeks later, rehiring Prasad after Makary personally vouched for his vision. Upon his return, Prasad reportedly did not adopt a more conciliatory tone. Instead, he moved to consolidate power, firing the official in charge of vaccine safety and surveillance and assuming those responsibilities himself. Reports from within the agency suggest he pushed out at least seven other leaders, creating what some staff members described to STAT as a work environment "rife with mistrust and paranoia."
Internal management issues have been a recurring theme of Prasad’s leadership. Despite working primarily from California and only visiting the FDA’s Silver Spring campus a few days a week, Prasad reportedly demanded an unusual degree of surveillance over his subordinates. Staff members alleged that he required them to make their professional calendars completely transparent to him while keeping his own schedule private. Furthermore, he reportedly instructed employees not to inform their direct supervisors if he requested private meetings with them, a move that disrupted the traditional chain of command. These management tactics led to several formal complaints being filed with human resources, further complicating his standing within the agency’s career ranks.
The broader context of Prasad’s exit is the mass exodus of veteran leadership at the FDA during the current administration. The Center for Drug Evaluation and Research (CDER), for instance, saw five different directors in the year 2025 alone. One of the most significant losses was Richard Pazdur, a legendary figure in cancer drug regulation, who retired in December. Pazdur’s departure was particularly stinging, as he cited concerns that political appointees were "corrupting" the agency’s rigorous scientific processes. His predecessor, George Tidmarsh, left amid a cloud of allegations regarding personal vendettas against former colleagues. This "steady clip" of departures has left the FDA with a vacuum of institutional knowledge at a time when the agency is being asked to fundamentally rethink its mission.
Prasad’s influence extended far beyond the walls of CBER. As a key ally of Commissioner Makary, he led the committee responsible for the "Commissioner’s National Priority Voucher," a program that guarantees a regulatory decision within 60 days for drugs deemed of high national importance. This role gave Prasad a platform to influence drug approvals that were technically outside his jurisdiction, effectively making him one of the most powerful medical arbiters in the federal government.
Nowhere has Prasad’s impact been more visible—or more controversial—than in the realm of vaccine policy. Under the oversight of Health Secretary Robert F. Kennedy Jr., a known skeptic of traditional vaccine protocols, the FDA has moved toward a more restrictive and skeptical stance. Prasad, along with top drug regulator Tracy Beth Høeg, took control of vaccine surveillance away from career staff. This shift in power culminated in a high-profile standoff with Moderna over its new flu vaccine. Prasad initially overruled his own staff and refused to review Moderna’s application, a decision that was only reversed after significant pressure from the White House. This incident highlighted the growing tension between the agency’s new ideological direction and the practicalities of maintaining a functioning relationship with the pharmaceutical industry.
As Prasad prepares to return to his academic post at UCSF, the FDA finds itself at a crossroads. His departure leaves a leadership void in a center that handles some of the most complex and expensive therapies in the history of medicine. While Makary has promised to name a successor before Prasad leaves at the end of April, the search will likely be complicated by the agency’s current reputation for internal strife and political volatility.
The legacy of Vinay Prasad at the FDA will be debated for years. To his supporters, he was a necessary disruptor who challenged a "cozy" relationship between regulators and Big Pharma, pushing for higher standards of evidence and more focus on individualized care. To his critics, he was a polarizing figure who prioritized ideology over institutional stability, slowed the delivery of life-saving treatments to rare disease patients, and undermined public confidence in vaccines.
The data regarding the "Prasad era" shows a marked shift in regulatory outcomes. The rejection of five major gene therapies in a single year is a statistical anomaly compared to the previous decade of CBER activity. Furthermore, the decision to limit Covid-19 boosters has placed the U.S. at odds with many other developed nations’ health organizations, creating a unique "American exception" in vaccine policy. As the agency searches for a new CBER director, it must grapple with whether to continue the path Prasad blazed or return to a more traditional, consensus-based regulatory framework. For now, the FDA remains an agency in transition, marked by the exit of a man who was arguably its most influential and controversial figure in recent memory.